GO:0031394 positive regulation of prostaglandin biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031394 describes any process that activates or increases the frequency, rate or extent of prostaglandin biosynthesis.
• Prostaglandin biosynthesis is driven by cyclooxygenase (COX) enzymes and terminal prostaglandin synthases, and is positively regulated by cytokines, growth factors and inflammatory cues.
• PGE2 is a major product of this pathway and suppresses T cell and TIL function, linking GO:0031394 to tumor immune evasion.
• Positive regulation of prostaglandin biosynthesis is central to chronic inflammation, cancer, and reproductive biology.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of regulators of this GO term.
• EDITGENE provides end-to-end CRISPR cell model and library screening services to study prostaglandin biosynthetic regulators.
Description
GO:0031394, positive regulation of prostaglandin biosynthetic process, is a Gene Ontology biological process term that captures any process which activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of prostaglandins. Prostaglandins are lipid mediators derived from arachidonic acid, and their production is tightly controlled at the level of biosynthetic enzymes and their upstream regulators. Understanding this term is essential because prostaglandin biosynthesis is a central node in inflammation, immune regulation, cancer progression and reproductive physiology. Mechanistically, positive regulation of prostaglandin biosynthesis often converges on the cyclooxygenase enzymes PTGS1 and PTGS2, which convert arachidonic acid to prostaglandin H2, the common precursor for terminal synthases such as PTGES, PTGFS and PTGDS. Cytokines, growth factors and tumor-derived signals can increase the expression or activity of these enzymes, thereby amplifying prostaglandin output. In tumors, this amplification produces PGE2, which impairs monocyte-mediated T cell stimulation and inhibits TIL expansion by disrupting IL-2 signaling and mitochondrial function. For researchers, GO:0031394 provides a structured framework to annotate and interrogate the regulatory inputs that drive prostaglandin production. Because the term is defined by positive regulation rather than by a single enzyme, it encompasses transcriptional, post-transcriptional and signaling events that converge on the biosynthetic machinery. This makes it a useful entry point for CRISPR screens, functional genomics and drug-target studies aimed at modulating prostaglandin-driven pathology.
positive regulation of prostaglandin biosynthetic process At A Glance
| GO ID | GO:0031394 |
|---|---|
| GO term | positive regulation of prostaglandin biosynthetic process |
| Ontology | biological_process |
| Synonym | activation of prostaglandin biosynthetic process; positive regulation of prostaglandin anabolism; positive regulation of prostaglandin biosynthesis; positive regulation of prostaglandin formation; positive regulation of prostaglandin synthesis; stimulation of prostaglandin biosynthetic process; up regulation of prostaglandin biosynthetic process; up-regulation of prostaglandin biosynthetic process; upregulation of prostaglandin biosynthetic process |
| Major function | Increases the rate or extent of prostaglandin formation, typically by upregulating cyclooxygenase and terminal synthase activity |
| Biological context | Inflammation, immune regulation, cancer immune evasion, reproductive biology |
| Key enzymes | PTGS1, PTGS2, PTGES, PTGFS, PTGDS |
| Representative regulator | PGE2-mediated signaling and cytokine crosstalk |
What Is GO:0031394?
GO:0031394 is defined as any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of prostaglandin. In other words, it is the positive regulatory arm of prostaglandin biosynthesis, covering signals and factors that upregulate the production of prostaglandins such as PGE2, PGF2alpha and PGD2.
Why Is positive regulation of prostaglandin biosynthetic process Important in Cell Biology?
GO:0031394 matters because prostaglandins are potent lipid mediators that shape inflammation, immunity and tumor progression, and their overproduction is a hallmark of many diseases. Positive regulation of prostaglandin biosynthesis is therefore a key mechanistic node for understanding how tumors evade immune attack and how chronic inflammatory states are sustained.
• Drives PGE2 production that inhibits TIL expansion and mitochondrial function in tumors.
• Enables cancer cells to impair monocyte-mediated T cell stimulation and evade immunity.
• Sustains chronic inflammation through prostaglandin-cytokine crosstalk.
• Regulates immune responses via PGE2 signaling in multiple cell types.
• Controls progesterone and PGF2alpha production in the corpus luteum.
• Influences renal prostaglandin biology and vascular homeostasis.
• Provides a target axis for anti-inflammatory and immuno-oncology therapeutics.
• Offers a defined GO term for functional genomics and CRISPR screening.
What Happens During positive regulation of prostaglandin biosynthetic process?
Upstream signals that initiate positive regulation
In simple terms: Inflammatory and growth signals tell the cell to make more prostaglandins.
Positive regulation of prostaglandin biosynthesis begins when extracellular cues such as cytokines, growth factors and tumor-derived factors engage receptors that activate downstream signaling. These signals converge on transcriptional and post-transcriptional programs that increase the capacity of the biosynthetic machinery.
Induction and activation of cyclooxygenase enzymes
In simple terms: The cell boosts the enzymes that convert arachidonic acid into the prostaglandin precursor.
A central step is the increased expression or activity of PTGS1 and PTGS2, which convert arachidonic acid to prostaglandin H2. Positive regulation of this step amplifies the flux into the prostaglandin biosynthetic pathway and is a common target of anti-inflammatory drugs.
Terminal synthase-mediated prostaglandin formation
In simple terms: Specialized enzymes turn the common precursor into specific prostaglandins like PGE2 and PGF2alpha.
Prostaglandin H2 is converted by terminal synthases such as PTGES, PTGFS and PTGDS into bioactive prostaglandins including PGE2, PGF2alpha and PGD2. Positive regulation of these enzymes determines the prostaglandin profile and the downstream biological effects.
PGE2 accumulation and immune modulation
In simple terms: The prostaglandin PGE2 builds up and changes how immune cells behave.
Increased prostaglandin biosynthesis leads to PGE2 accumulation, which inhibits TIL expansion by disrupting IL-2 signaling and mitochondrial function. Cancer cells can also impair monocyte-mediated T cell stimulation through prostaglandin-dependent mechanisms, linking this GO term to immune evasion.
Feedback and crosstalk with cytokine networks
In simple terms: Prostaglandins talk back to the immune system, creating a loop that can keep inflammation going.
Prostaglandins participate in crosstalk with cytokines, which can further reinforce or modulate the biosynthetic program. This feedback shapes chronic inflammation and the tumor microenvironment, making positive regulation of prostaglandin biosynthesis a dynamic and context-dependent process.
Key Genes Involved in GO:0031394 positive regulation of prostaglandin biosynthetic process
The following genes and proteins are central to positive regulation of prostaglandin biosynthetic process, based on their established roles in prostaglandin biosynthesis and its upstream control.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTGS1 | Constitutive cyclooxygenase that converts arachidonic acid to PGH2 | Baseline prostaglandin production; KO models for housekeeping biosynthesis |
| PTGS2 | Inducible cyclooxygenase upregulated by inflammatory signals | Central node in positive regulation; target of COX-2 inhibitors |
| PTGES | Terminal synthase for PGE2 production | Determines PGE2 output; relevant to immune suppression |
| PTGFS | Terminal synthase for PGF2alpha production | Reproductive biology and corpus luteum function |
| PTGDS | Terminal synthase for PGD2 production | Allergic and inflammatory responses |
| PLA2G4A | Releases arachidonic acid substrate for prostaglandin synthesis | Upstream control of substrate availability |
| IL1B | Pro-inflammatory cytokine that induces prostaglandin biosynthesis | Positive regulator in inflammation models |
| TNF | Cytokine that amplifies prostaglandin production | Inflammatory crosstalk studies |
| IL2 | Cytokine whose signaling is disrupted by PGE2 in TILs | Immune function readout in prostaglandin-high contexts |
| PTGER2 | PGE2 receptor mediating immune modulation | Receptor-level control of prostaglandin effects |
| PTGER4 | PGE2 receptor involved in immune regulation | Target for modulating prostaglandin-driven suppression |
| NFKB1 | Transcription factor driving PTGS2 expression | Transcriptional regulation of the biosynthetic program |
| MAPK1 | Kinase pathway contributing to PTGS2 induction | Signaling node in positive regulation |
| CALCA | Calcitonin-related peptide linked to prostaglandin signaling | Renal and vascular prostaglandin biology |
| AR | Aromatase regulation linked to prostaglandin production | Breast cancer and hormonal crosstalk |
| CYP19A1 | Aromatase whose expression is tissue-selectively regulated with prostaglandins | Breast cancer therapy implications |
| VEGFA | Angiogenic factor influenced by prostaglandin pathways | Tumor microenvironment studies |
| PTGIR | Prostacyclin receptor mediating prostaglandin effects | Vascular and inflammatory readouts |
How Is positive regulation of prostaglandin biosynthetic process Regulated?
Positive regulation of prostaglandin biosynthetic process is controlled at multiple levels, including transcriptional induction of PTGS2 by inflammatory transcription factors, post-transcriptional stabilization of COX-2 mRNA, and signaling through cytokine and growth factor pathways. Prostaglandin-cytokine crosstalk creates feedback loops that can sustain or dampen the biosynthetic program. In tumors, cancer cell-intrinsic signals can upregulate prostaglandin production and impair monocyte-mediated T cell stimulation, while PGE2 further inhibits TIL expansion by disrupting IL-2 signaling and mitochondrial function. These layers of regulation make the pathway responsive to the microenvironment and amenable to CRISPR-based perturbation.
positive regulation of prostaglandin biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTGS2 | Chronic inflammation and cancer immune evasion | KO and overexpression cell models in tumor lines |
| PTGES | PGE2-driven immune suppression | Knockout and point-mutation models for enzymatic activity |
| PTGFS | Reproductive disorders and luteal dysfunction | Knock-in reporter models in ovarian cell lines |
| PTGER2 | Immune modulation and inflammation | Overexpression and KO models in immune cells |
| CYP19A1 | Breast cancer and hormonal crosstalk | Knock-in and overexpression models in breast cancer cells |
Cancer immune evasion
Positive regulation of prostaglandin biosynthesis contributes to cancer immune evasion by increasing PGE2, which impairs monocyte-mediated T cell stimulation and inhibits TIL expansion through disruption of IL-2 signaling and mitochondrial function. This links GO:0031394 directly to immuno-oncology and resistance to T cell-based therapies.
Chronic inflammation
Prostaglandin-cytokine crosstalk is a hallmark of chronic inflammation, where sustained positive regulation of prostaglandin biosynthesis amplifies inflammatory signaling and tissue damage. Targeting this pathway is a long-standing strategy in anti-inflammatory drug development.
Reproductive and endocrine disorders
Prostaglandins are critical for corpus luteum function and progesterone regulation, and positive regulation of their biosynthesis influences PGF2alpha production in reproductive tissues. Dysregulation can affect luteal function and reproductive outcomes.
Renal and vascular biology
Renal prostaglandins participate in vascular and electrolyte homeostasis, and their positive regulation is relevant to renal physiology and disease. Tissue-selective regulation of prostaglandin-related pathways also intersects with aromatase expression in breast cancer therapy.
From positive regulation of prostaglandin biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is PTGS2 required for prostaglandin-driven immune evasion? | PTGS2 knockout in tumor cell lines |
| Does a specific PTGES point mutation alter PGE2 output? | Point-mutation knock-in of catalytic residues |
| Can a tagged PTGES reporter track prostaglandin biosynthesis? | Tagged knock-in for imaging and proteomics |
| Does overexpression of PTGS2 increase PGE2 and suppress T cells? | Overexpression cell model in tumor lines |
| Which regulators of prostaglandin biosynthesis are essential? | CRISPR library screening in inflammatory or tumor models |
| How does PGE2 receptor signaling feed back on biosynthesis? | PTGER2/PTGER4 KO and overexpression models |
How to Study the positive regulation of prostaglandin biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on prostaglandin biosynthesis | Causal gene validation in tumor and immune cells |
| Point-mutation knock-in | Specific residue contributions to enzyme activity | Catalytic mechanism studies |
| RNA-seq | Transcriptional changes in biosynthetic enzymes | Pathway profiling after perturbation |
| Proteomics | Protein-level changes in prostaglandin machinery | Regulator discovery |
| Lipid mass spectrometry | Prostaglandin species and flux | Direct pathway output measurement |
| T cell expansion assay | PGE2-mediated suppression of TILs | Immuno-oncology functional readout |
| Monocyte-T cell co-culture | Immune evasion mechanisms | Tumor microenvironment studies |
| CRISPR library screening | Essential regulators of prostaglandin biosynthesis | Genome-wide discovery |
CRISPR knockout and point-mutation studies
CRISPR knockout of PTGS2, PTGES and related genes can establish causality for positive regulation of prostaglandin biosynthesis, while point mutations can dissect catalytic and regulatory residues. These approaches are essential for distinguishing enzyme activity from expression-level effects.
Transcriptomic and proteomic profiling
RNA-seq and proteomics can quantify changes in prostaglandin biosynthetic enzymes and upstream regulators following perturbation. Such profiling helps map the signaling networks that positively regulate prostaglandin production.
Lipid mediator quantification
Mass spectrometry-based measurement of PGE2, PGF2alpha and related prostaglandins provides direct readouts of biosynthetic flux. These measurements are critical for validating functional effects of CRISPR perturbations.
Immune functional assays
T cell expansion and mitochondrial function assays can assess the downstream consequences of prostaglandin biosynthesis, as PGE2 inhibits TIL expansion by disrupting IL-2 signaling and mitochondrial function. Monocyte-T cell co-culture systems can further test immune evasion mechanisms.
How CRISPR Can Be Used to Study GO:0031394 positive regulation of prostaglandin biosynthetic process
Knockout
CRISPR knockout of PTGS2, PTGES or upstream regulators can abolish or reduce positive regulation of prostaglandin biosynthesis, providing causal evidence for their roles. Knockout models are widely used to test whether a gene is required for PGE2 production and downstream immune suppression.
Point Mutation
Point-mutation knock-in can dissect catalytic residues in PTGS2 or PTGES and separate enzymatic activity from protein abundance. Such models are valuable for understanding how specific residues contribute to prostaglandin biosynthesis.
Knock-in
Tagged knock-in of PTGES or PTGS2 enables imaging and proteomic tracking of the biosynthetic machinery in live cells. Reporter knock-in can also monitor pathway activation in response to inflammatory signals.
Overexpression
Overexpression of PTGS2 or terminal synthases can amplify prostaglandin production and model the pathological overactivation seen in cancer and chronic inflammation. These models are useful for testing inhibitors and immune evasion mechanisms.
How EDITGENE Supports positive regulation of prostaglandin biosynthetic process Research
Researchers studying positive regulation of prostaglandin biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in prostaglandin production, immune modulation or tumor progression. EDITGENE provides CRISPR-based cell model and screening services to enable such causal studies with publication-ready rigor.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of prostaglandin biosynthetic process research.
Frequently Asked Questions About positive regulation of prostaglandin biosynthetic process
What is GO:0031394?
GO:0031394 is the Gene Ontology term for positive regulation of prostaglandin biosynthetic process, defined as any process that activates or increases the frequency, rate or extent of prostaglandin formation.
What genes are involved in positive regulation of prostaglandin biosynthetic process?
Key genes include PTGS1, PTGS2, PTGES, PTGFS, PTGDS and upstream regulators such as IL1B and TNF.
How is prostaglandin biosynthesis positively regulated?
It is positively regulated by inflammatory cytokines, growth factors and signaling pathways that increase cyclooxygenase and terminal synthase expression or activity.
Why is PGE2 important in cancer immunity?
PGE2 inhibits TIL expansion by disrupting IL-2 signaling and mitochondrial function, and cancer cells can impair monocyte-mediated T cell stimulation.
What diseases are linked to GO:0031394?
It is linked to cancer immune evasion, chronic inflammation, reproductive disorders and renal/vascular biology.
How can CRISPR help study prostaglandin biosynthesis?
CRISPR knockout, point mutation, knock-in and overexpression models can establish causal roles for genes in prostaglandin production and downstream immune effects.
What is the role of PTGS2 in this pathway?
PTGS2 is an inducible cyclooxygenase that converts arachidonic acid to prostaglandin H2, a key step in prostaglandin biosynthesis.
Which methods measure prostaglandin biosynthesis?
Lipid mass spectrometry, RNA-seq, proteomics and immune functional assays are commonly used to measure prostaglandin output and its effects.
What is the difference between PTGS1 and PTGS2?
PTGS1 is constitutively expressed, while PTGS2 is inducible by inflammatory signals and is a major node in positive regulation.
How does prostaglandin-cytokine crosstalk work?
Prostaglandins and cytokines mutually regulate each other, creating feedback loops that sustain or modulate inflammation.
Conclusion
GO:0031394, positive regulation of prostaglandin biosynthetic process, is a central biological process that governs the production of lipid mediators with profound effects on immunity, inflammation and cancer. Its definition and annotation provide a rigorous framework for studying how upstream signals increase prostaglandin output and how this drives disease. By combining CRISPR knockout, point-mutation, knock-in, overexpression and library screening approaches, researchers can causally dissect the regulators of this pathway and identify new therapeutic targets. EDITGENE offers integrated services to accelerate such discoveries with publication-ready cell models and bioinformatics support.
References
- 1. Elewaut A et al.. 2025. Cancer cells impair monocyte-mediated T cell stimulation to evade immunity.. Nature 637(8046):716-725 PMID: 39604727
- 2. Morotti M et al.. 2024. PGE(2) inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function.. Nature 629(8011):426-434 PMID: 38658764
- 3. Schuster VL. 2002. Prostaglandin transport.. Prostaglandins Other Lipid Mediat 68-69:633-47 PMID: 12432949
- 4. Terragno NA et al.. 1976. Renal prostaglandins.. Adv Prostaglandin Thromboxane Res 2:561-71 PMID: 824936
- 5. Diaz FJ et al.. 2002. Regulation of progesterone and prostaglandin F2alpha production in the CL.. Mol Cell Endocrinol 191(1):65-80 PMID: 12044920
- 6. Krishnan AV et al.. 2010. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.. Endocrinology 151(1):32-42 PMID: 19906814
- 7. Yao C et al.. 2019. Prostaglandin-cytokine crosstalk in chronic inflammation.. Br J Pharmacol 176(3):337-354 PMID: 30381825
- 8. Kalinski P. 2012. Regulation of immune responses by prostaglandin E2.. J Immunol 188(1):21-8 PMID: 22187483
